Published in AIDS Weekly and Law, May 13th, 2004
The data presented showed that IR103, an immune-based therapy comprised of a gp120-depleted HIV-1 immunogen (Remune) and a second-generation immunostimulatory oligonucleotide adjuvant (Amplivax developed by Hybridon, Inc.[HBY]), demonstrated potent HIV-1 specific immunogenicity.
These data warrant continued development of IR103 as a potential therapy for individuals living with HIV.
"These experimental data on IR103...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.